# A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications

Study · id `cardio:ct-nct07835984` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07835984](<https://clinicaltrials.gov/study/NCT07835984>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07835984

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 560 participants.

## Technical summary

Registry record NCT07835984. Randomized; quadruple masking; primary purpose treatment. Start 2026-10 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 560 participants (planned count; ClinicalTrials.gov record NCT07835984, source copy `cardio:ctgov-nct07835984-2026-09-23`, retrieved 2026-10-26)
- Planned start: 2026-10 (anticipated) (ClinicalTrials.gov record NCT07835984, source copy `cardio:ctgov-nct07835984-2026-09-23`, retrieved 2026-10-26)
- Primary completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07835984, source copy `cardio:ctgov-nct07835984-2026-09-23`, retrieved 2026-10-26)
- Completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT07835984, source copy `cardio:ctgov-nct07835984-2026-09-23`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07835984, source copy `cardio:ctgov-nct07835984-2026-09-23`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07835984-2026-09-23`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate Efficacy and Safety of GW906 Used as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by One or Two Antihypertensive Medications
- Condition: Hypertension
- Intervention (Drug): GW906
- Intervention (Drug): Placebo
- Lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd. (`cardio:org-shenzhen-salubris-pharmaceuticals-co-ltd`)

## Provenance

Content hash: 9a116b3672db4acbc2a167022d4335600e08e9c35338831182376a95264a9653
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
